Russell Investments Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,328
| Closed | -$23.2K | – | 4187 |
|
|
2025
Q2 | $23.2K | Sell |
2,328
-42,856
| -95% | -$345K | ﹤0.01% | 3161 |
|
|
2025
Q1 | $270K | Sell |
45,184
-12,041
| -21% | -$88.4K | ﹤0.01% | 2505 |
|
|
2024
Q4 | $439K | Buy |
57,225
+30,619
| +115% | +$263K | ﹤0.01% | 2313 |
|
|
2024
Q3 | $272K | Buy |
26,606
+25,573
| +2,476% | +$390K | ﹤0.01% | 2442 |
|
|
2024
Q2 | $15.3K | Sell |
1,033
-38,098
| -97% | -$546K | ﹤0.01% | 2989 |
|
|
2024
Q1 | $534K | Sell |
39,131
-377
| -1% | -$4.11K | ﹤0.01% | 2184 |
|
|
2023
Q4 | $433K | Buy |
39,508
+15,757
| +66% | +$156K | ﹤0.01% | 2265 |
|
|
2023
Q3 | $260K | Sell |
23,751
-1,305
| -5% | -$16.7K | ﹤0.01% | 2433 |
|
|
2023
Q2 | $332K | Buy |
25,056
+145
| +0.6% | +$2.07K | ﹤0.01% | 2347 |
|
|
2023
Q1 | $339K | Sell |
24,911
-281
| -1% | -$5.04K | ﹤0.01% | 2373 |
|
|
2022
Q4 | $492K | Sell |
25,192
-6,900
| -22% | -$135K | ﹤0.01% | 2294 |
|
|
2022
Q3 | $609K | Sell |
32,092
-8,308
| -21% | -$191K | ﹤0.01% | 2163 |
|
|
2022
Q2 | $832K | Buy |
40,400
+23,600
| +140% | +$560K | ﹤0.01% | 2044 |
|
|
2022
Q1 | $540K | Buy |
16,800
+12,400
| +282% | +$451K | ﹤0.01% | 2204 |
|
|
2021
Q4 | $204K | Buy |
+4,400
| New | +$146K | ﹤0.01% | 2717 |
|
|
2021
Q3 | – | Sell |
-13,399
| Closed | -$343K | – | 3126 |
|
|
2021
Q2 | $343K | Buy |
13,399
+7,869
| +142% | +$187K | ﹤0.01% | 2735 |
|
|
2021
Q1 | $189K | Buy |
+5,530
| New | +$200K | ﹤0.01% | 2849 |
|
Other funds holding ITOS
Russell Investments Group's ITOS Position: Q3 2025 in Review
Russell Investments Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 2,328 shares — an estimated $23.2K sold.
Russell Investments Group first reported a position in ITOS in Q1 2021 and held it in 17 quarters. The position peaked at $832K in Q2 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Russell Investments Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Russell Investments Group sold 2,328 iTeos Therapeutics shares in Q3 2025, an estimated $23.2K.
- Russell Investments Group first reported a position in iTeos Therapeutics in Q1 2021 and held it in 17 quarters.
- Russell Investments Group's iTeos Therapeutics position peaked at $832K in Q2 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Russell Investments Group's 13F filing for Q3 2025, filed 13 Nov 2025.